{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:00:09Z","timestamp":1786114809403,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.iac.2026.04.009","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:25:42Z","timestamp":1783639542000},"page":"479-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Topical Therapy for Atopic Dermatitis"],"prefix":"10.1016","volume":"46","author":[{"given":"Maria Gnarra","family":"Buethe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn","family":"Kellogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Joon","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.iac.2026.04.009_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","article-title":"Public Health Burden and Epidemiology of Atopic Dermatitis","volume":"35","author":"Silverberg","year":"2017","journal-title":"Dermatol Clin"},{"issue":"5","key":"10.1016\/j.iac.2026.04.009_bib2","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/ijms23052684","article-title":"Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets","volume":"23","author":"Fania","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.iac.2026.04.009_bib3","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jaci.2018.01.019","article-title":"Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration","volume":"141","author":"Baurecht","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2026.04.009_bib4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.16934","article-title":"Atopic dermatitis: the skin barrier and beyond","volume":"180","author":"Tsakok","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2026.04.009_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","article-title":"Guidelines of care for the management of atopic dermatitis in adults with topical therapies","volume":"89","author":"Sidbury","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2026.04.009_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.iac.2026.04.009_bib7","first-page":"0213","article-title":"Systematic Review of Steroid Phobia in Atopic Dermatitis","volume":"derm.2023","author":"Fitzmaurice","year":"2024","journal-title":"Dermatitis\u00ae"},{"issue":"4","key":"10.1016\/j.iac.2026.04.009_bib9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2026.04.009_bib10","doi-asserted-by":"crossref","first-page":"e24137","DOI":"10.4161\/jkst.24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAK-STAT"},{"issue":"3","key":"10.1016\/j.iac.2026.04.009_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamadermatol.2023.5509","article-title":"Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials","volume":"160","author":"Ireland","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2026.04.009_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","article-title":"A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis","volume":"23","author":"Bissonnette","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2026.04.009_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","article-title":"Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies","volume":"22","author":"Gong","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2026.04.009_bib14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.04.009_bib15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.iac.2026.04.009_bib16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies","volume":"88","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2026.04.009_bib17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.anai.2022.12.033","article-title":"Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis","volume":"130","author":"Leung","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.04.009_bib18","doi-asserted-by":"crossref","first-page":"AB1","DOI":"10.1016\/j.jaci.2023.11.027","article-title":"Efficacy and Safety of Ruxolitinib Cream Among Children With Atopic Dermatitis Aged 2 to 6 Years and 7 to <12 Years: Results from a Phase 3 Double-Blind Vehicle-Controlled Study","volume":"153","author":"Soong","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2026.04.009_bib19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.iac.2026.04.009_bib20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","article-title":"Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex","volume":"28","author":"Schafer","year":"2016","journal-title":"Cell Signal"},{"issue":"3","key":"10.1016\/j.iac.2026.04.009_bib21","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","article-title":"Phosphodiesterase 4 inhibitors","volume":"78","author":"Zebda","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.iac.2026.04.009_bib22","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials","volume":"328","author":"Lebwohl","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.iac.2026.04.009_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.36849\/JDD.7295","article-title":"The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study","volume":"22","author":"Gooderham","year":"2023","journal-title":"J Drugs Dermatol JDD"},{"issue":"5","key":"10.1016\/j.iac.2026.04.009_bib24","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jaad.2023.12.065","article-title":"Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial","volume":"90","author":"Blauvelt","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2026.04.009_bib31","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor\u2013modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2026.04.009_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/pr.114.009001","article-title":"The Aryl Hydrocarbon Receptor in Barrier Organ Physiology, Immunology, and Toxicology","volume":"67","author":"Esser","year":"2015","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.iac.2026.04.009_bib33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jid.2018.10.019","article-title":"AHR Regulates Metabolic Reprogramming to Promote SIRT1-Dependent Keratinocyte Differentiation","volume":"139","author":"Sutter","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.iac.2026.04.009_bib34","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans","volume":"137","author":"Smith","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.iac.2026.04.009_bib35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-022-00712-0","article-title":"What\u2019s New in Topicals for Atopic Dermatitis?","volume":"23","author":"Kleinman","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2026.04.009_bib36","doi-asserted-by":"crossref","first-page":"s194","DOI":"10.25251\/skin.7.supp.194","article-title":"Tapinarof Inhibits the Formation, Cytokine Production, and Persistence of Resident Memory T Cells In Vitro","volume":"7","author":"Mooney","year":"2023","journal-title":"J of Skin"},{"key":"10.1016\/j.iac.2026.04.009_bib37","doi-asserted-by":"crossref","first-page":"1323405","DOI":"10.3389\/falgy.2024.1323405","article-title":"Aryl hydrocarbon receptor and IL-13 signaling crosstalk in human keratinocytes and atopic dermatitis","volume":"5","author":"Proper","year":"2024","journal-title":"Front Allergy"},{"issue":"Supplement_2","key":"10.1016\/j.iac.2026.04.009_bib39","doi-asserted-by":"crossref","first-page":"ii17","DOI":"10.1093\/bjd\/ljad498.021","article-title":"514 - Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age","volume":"190","author":"Silverberg","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2026.04.009_bib40","doi-asserted-by":"crossref","unstructured":"Simpson E, Hebert A, Sofen H, et al. Tapinarof Cream 1% Once Daily in Adults and Children Down to 2 Years of Age with Moderate to Severe Atopic Dermatitis in Two Phase 3 Trials: Patient reported Outcomes. Presented at: March 8, 2024; American Academy of Dermatology (AAD) Congress, San Diego, California.","DOI":"10.1016\/j.jaad.2024.07.358"},{"key":"10.1016\/j.iac.2026.04.009_bib41","unstructured":"Available at: https:\/\/dermavant.com\/dermavant-announces-positive-data-from-the-adoring-phase-3-development-program-in-atopic-dermatitis-with-vtama-tapinarof-cream-1-in-adults-and-children-as-young-as-2-years-old\/."},{"issue":"5","key":"10.1016\/j.iac.2026.04.009_bib42","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jaad.2023.02.065","article-title":"A multimodal initiative improves general pediatric provider management of atopic dermatitis in children: A prospective interventional study","volume":"89","author":"Lee","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.iac.2026.04.009_bib43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/09546634.2019.1708240","article-title":"Comparing the effects of proactive treatment with tacrolimus ointment and mometasone furoate on the epidermal barrier structure and ceramide levels of patients with atopic dermatitis","volume":"32","author":"D\u00e4hnhardt","year":"2021","journal-title":"J Dermatol Treat"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T21:35:35Z","timestamp":1785965735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856126000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0889856126000378"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2026.04.009","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical Therapy for Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2026.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}